Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified

Omnicell

(

OMCL

) as a strong and under the radar candidate. In addition to specific proprietary factors, Trade-Ideas identified Omnicell as such a stock due to the following factors:

  • OMCL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $4.1 million.
  • OMCL is making at least a new 3-day high.
  • OMCL has a PE ratio of 42.9.
  • OMCL is mentioned 0.97 times per day on StockTwits.
  • OMCL has not yet been mentioned on StockTwits today.
  • OMCL is currently in the upper 20% of its 1-year range.
  • OMCL is in the upper 35% of its 20-day range.
  • OMCL is in the upper 45% of its 5-day range.
  • OMCL is currently trading above yesterday's high.

'Strong and Under the Radar' stocks tend to be worthwhile stocks to watch for a variety of factors including historical back testing and price action. Market technicians refer to such stocks as being in an accumulation phase before a mark-up and peak. Traders and hedge funds have frequently found that these types of stocks continue to build a solid price base and then ultimately spike higher and peak when others 'discover' how good the stock is performing. By leveraging the social discovery aspect of StockTwits we are highlighting stocks that don't currently receive much attention from retail investors, but we suspect may soon garner more attention.

Scroll to Continue

TheStreet Recommends

EXCLUSIVE OFFER: Get the inside scoop on opportunities in OMCL with the Ticky from Trade-Ideas. See the FREE profile for OMCL NOW at Trade-Ideas

More details on OMCL:

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates in two segments, Automation and Analytics, and Medication Adherence. OMCL has a PE ratio of 42.9. Currently there are 3 analysts that rate Omnicell a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Omnicell has been 210,500 shares per day over the past 30 days. Omnicell has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. The stock has a beta of 0.97 and a short float of 1.7% with 5.98 days to cover. Shares are up 8.8% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Omnicell as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:

  • Powered by its strong earnings growth of 31.57% and other important driving factors, this stock has surged by 31.40% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, OMCL should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • OMNICELL INC has improved earnings per share by 31.6% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, OMNICELL INC increased its bottom line by earning $0.83 versus $0.67 in the prior year. This year, the market expects an improvement in earnings ($1.36 versus $0.83).
  • Despite its growing revenue, the company underperformed as compared with the industry average of 22.2%. Since the same quarter one year prior, revenues rose by 14.9%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • OMCL has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. To add to this, OMCL has a quick ratio of 1.86, which demonstrates the ability of the company to cover short-term liquidity needs.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null